{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:33:33Z","timestamp":1790127213848,"version":"4.0.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"15","license":[{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The use of buprenorphine, methadone, and long-acting naltrexone for treatment of opioid use disorder (OUD) is discussed, including a review of current literature detailing treatment approaches and action steps to optimize treatment in acute care and office-based settings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>The U.S. epidemic of opioid-related deaths has been driven by misuse of prescription opioids and, increasingly, illicit drugs such as heroin, fentanyl, and fentanyl analogs, necessitating a refocusing of treatment efforts on expanding access to life-saving, evidence-based OUD pharmacotherapy. Inpatient treatment of opioid withdrawal includes acute symptom control through a combination of nonopioid medications and long-term pharmacotherapy to lessen opioid craving and facilitate stabilization and recovery. Methadone and buprenorphine reduce opioid craving, increase treatment retention, reduce illicit opioid use, and increase overall survival. Buprenorphine has logistical advantages over methadone, such as greater flexibility of treatment setting and less risk of adverse effects. Studies have shown the efficacy of long-acting injectable naltrexone to be comparable to that of buprenorphine if patients are detoxified prior to initiation of therapy; however, patients with active OUD are often not able to complete the week-long period of opioid abstinence needed prior to initiation of naltrexone injections. Although buprenorphine is preferred by many patients and can be prescribed in office-based settings, there remains a paucity of physicians certified to prescribe it.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Buprenorphine has become the medication of choice for many patients with OUD, but its use is limited by the low number of physicians certified to prescribe the agent. Other agents studied for treatment of OUD include methadone and naltrexone.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxz105","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T13:50:41Z","timestamp":1594993841000},"page":"1097-1103","source":"Crossref","is-referenced-by-count":84,"title":["Medications for management of opioid use disorder"],"prefix":"10.1093","volume":"76","author":[{"given":"Jennifer L","family":"Koehl","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Duquesne University, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J","family":"Bridgeman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"issue":"5152","key":"2020071623575663300_CIT0001","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2013-2017","volume":"67","author":"Scholl","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"1","key":"2020071623575663300_CIT0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/08897077.2016.1261070","article-title":"Turning the tide or riptide? The changing opioid epidemic","volume":"38","author":"Kertesz","year":"2017","journal-title":"Subst Abus."},{"key":"2020071623575663300_CIT0003","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"3","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"key":"2020071623575663300_CIT0004","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"issue":"16","key":"2020071623575663300_CIT0005","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial","volume":"313","author":"D\u2019Onofrio","year":"2015","journal-title":"JAMA."},{"issue":"3","key":"2020071623575663300_CIT0006","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/08897077.2018.1509251","article-title":"Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the veterans health administration","volume":"39","author":"Valenstein-Mah","year":"2018","journal-title":"Subst Abus."},{"issue":"1","key":"2020071623575663300_CIT0007","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Ann Fam Med."},{"issue":"3","key":"2020071623575663300_CIT0008","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am J Drug Alcohol Abuse."},{"issue":"2","key":"2020071623575663300_CIT0009","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The clinical opiate withdrawal scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoactive Drugs."},{"issue":"4","key":"2020071623575663300_CIT0010","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s13181-018-0685-1","article-title":"Pharmacologic treatment of opioid use disorder: a review of pharmacotherapy, adjuncts, and toxicity","volume":"14","author":"Toce","year":"2018","journal-title":"J Med Toxicol."},{"issue":"4","key":"2020071623575663300_CIT0011","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/npp.1993.66","article-title":"Beta-adrenergic antagonists attenuate somatic and aversive signs of opiate withdrawal","volume":"9","author":"Harris","year":"1993","journal-title":"Neuropsychopharmacology."},{"issue":"4","key":"2020071623575663300_CIT0012","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/J354v19n04_05","article-title":"Pharmacokinetics of methadone","volume":"19","author":"Lugo","year":"2005","journal-title":"J Pain Palliat Care Pharmacother."},{"issue":"14","key":"2020071623575663300_CIT0013","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"2020071623575663300_CIT0014","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/bcp.12576","article-title":"Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity","volume":"79","author":"Mouly","year":"2015","journal-title":"Br J Clin Pharmacol."},{"issue":"7","key":"2020071623575663300_CIT0015","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1399-6576.2008.01597.x","article-title":"Clinical pharmacology of methadone for pain","volume":"52","author":"Fredheim","year":"2008","journal-title":"Acta Anaesthesiol Scand."},{"issue":"7","key":"2020071623575663300_CIT0016","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.amjcard.2004.11.055","article-title":"Impact of methadone treatment on cardiac repolarization and conduction in opioid users","volume":"95","author":"Martell","year":"2005","journal-title":"Am J Cardiol."},{"issue":"11","key":"2020071623575663300_CIT0017","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1592\/phco.2005.25.11.1523","article-title":"Effects of methadone on QT-interval dispersion","volume":"25","author":"Krantz","year":"2005","journal-title":"Pharmacotherapy."},{"issue":"2","key":"2020071623575663300_CIT0018","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jpainsymman.2006.02.010","article-title":"Opioid switching from morphine to methadone causes a minor but not clinically significant increase in qtc time: A prospective 9-month follow-up study","volume":"32","author":"Fredheim","year":"2006","journal-title":"J Pain Symptom Manage."},{"issue":"1","key":"2020071623575663300_CIT0019","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jpainsymman.2015.08.003","article-title":"Methadone use and the risk of hypoglycemia for inpatients with cancer pain","volume":"51","author":"Flory","year":"2016","journal-title":"J Pain Symptom Manage."},{"issue":"6","key":"2020071623575663300_CIT0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.ADM.0000435321.39251.d7","article-title":"Safe methadone induction and stabilization: report of an expert panel","volume":"7","author":"Baxter","year":"2013","journal-title":"J Addict Med."},{"key":"2020071623575663300_CIT0021","volume-title":"Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants","year":"2018"},{"issue":"5","key":"2020071623575663300_CIT0022","doi-asserted-by":"crossref","first-page":"e19527","DOI":"10.1371\/journal.pone.0019527","article-title":"Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response","volume":"6","author":"Fonseca","year":"2011","journal-title":"Plos One."},{"issue":"7","key":"2020071623575663300_CIT0023","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"2020071623575663300_CIT0024","volume-title":"Suboxone (buprenorphine and naloxone) prescribing information","year":"2018"},{"key":"2020071623575663300_CIT0025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1360-0443.2012.04036.x","article-title":"Maternal opioid treatment: human experimental research (MOTHER)\u2013approach, issues and lessons learned","volume":"107","author":"Jones","year":"2012","journal-title":"Addiction."},{"key":"2020071623575663300_CIT0026","volume-title":"Vivitrol (naltrexone for extended-release injectable suspension) prescribing information","year":"2015"},{"key":"2020071623575663300_CIT0027","volume-title":"Revia (naltrexone) prescribing information","year":"2013"},{"key":"2020071623575663300_CIT0028","first-page":"CD001333","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"4","author":"Minozzi","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"2020071623575663300_CIT0029","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1530-0277.2006.00052.x","article-title":"Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone","volume":"30","author":"Dunbar","year":"2006","journal-title":"Alcohol Clin Exp Res."},{"issue":"10","key":"2020071623575663300_CIT0030","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40263-013-0110-x","article-title":"Extended-release intramuscular naltrexone (VIVITROL\u00ae): a review of its use in the prevention of relapse to opioid dependence in detoxified patients","volume":"27","author":"Syed","year":"2013","journal-title":"CNS Drugs."},{"key":"2020071623575663300_CIT0031","volume-title":"Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis","author":"Ma"},{"key":"2020071623575663300_CIT0032","author":"Department of Defense and Department of Veterans Affairs","year":"2015"},{"issue":"10118","key":"2020071623575663300_CIT0033","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet."},{"issue":"10","key":"2020071623575663300_CIT0034","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40264-018-0653-3","article-title":"Review of case narratives from fatal overdoses associated with injectable naltrexone for opioid dependence","volume":"41","author":"Saucier","year":"2018","journal-title":"Drug Saf."},{"issue":"7","key":"2020071623575663300_CIT0035","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction."},{"key":"2020071623575663300_CIT0036","first-page":"CD011117","article-title":"Opioid agonist treatment for pharmaceutical opioid dependent people","volume":"5","author":"Nielsen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2020071623575663300_CIT0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","article-title":"Why aren\u2019t physicians prescribing more buprenorphine?","volume":"78","author":"Huhn","year":"2017","journal-title":"J Subst Abuse Treat."},{"issue":"2","key":"2020071623575663300_CIT0038","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1370\/afm.1595","article-title":"Barriers to primary care physicians prescribing buprenorphine","volume":"12","author":"Hutchinson","year":"2014","journal-title":"Ann Fam Med."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/15\/1097\/28938522\/zxz105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/15\/1097\/28938522\/zxz105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T13:51:29Z","timestamp":1594993889000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/76\/15\/1097\/5532635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,18]]},"references-count":38,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2019,7,18]]},"published-print":{"date-parts":[[2019,7,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz105","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,1]]},"published":{"date-parts":[[2019,7,18]]}}}